Delhi Seizes 481 Counterfeit Abhayrab Rabies Vaccine Units, Traces Supply to Kanpur Agency

The news

New Delhi. The Delhi Drugs Control (DDC) Department has seized counterfeit rabies vaccine worth ₹2 lakh from a firm in Central Delhi’s Bhagirath Palace and traced the supply to an agency in Kanpur, a Delhi government release said on Monday, September 21, The Indian Express reports. Raids at three premises of the firm, on the direction of Delhi Health Minister Pankaj Kumar Singh, led to the seizure of 481 units of Purified Vero Cell Rabies Vaccine sold under the brand name Abhayrab. The original manufacturer, Human Biologicals Institute, Telangana — the human health and vaccine division of Indian Immunologicals Limited (IIL) — confirmed that the batch was counterfeit and had not been released by the company. Of the seized stock, 120 vials were collected as legal samples and sent for testing to the Central Research Institute (CRI), Kasauli; the remaining 361 units, along with seven purchase invoices, were seized under relevant sections of the Drugs and Cosmetics Act, 1940. The firm told investigators it had sourced the vaccine from a Kanpur agency; the Uttar Pradesh State Drug Department then raided two locations, including the agency’s premises, and confirmed it as the source. The DDC Department is now tracing the distribution network. “Rabies is a fatal and serious disease, and we cannot compromise on the quality of the vaccine,” Mr. Singh said, promising action “even against suppliers outside Delhi”. On August 27, the Drugs Controller General of India had written to all State drug control departments asking them to step up vigilance on the movement, distribution and availability of a misbranded vaccine batch. IIL has said every batch of Abhayrab undergoes independent government testing before release, and that vaccines supplied through authorised channels, including hospitals and licensed pharmacies, remain unaffected. A “Vero cell” vaccine is made by growing the virus in a standard laboratory cell line and inactivating it. A counterfeit vaccine is especially dangerous because rabies vaccine is given after an animal bite, when the person has no second chance: once symptoms appear, rabies is almost always fatal. The paper recalls a 2025 study by the Indian Council of Medical Research, published in The Lancet Infectious Diseases and based on a survey of nearly 79,000 households, which estimated 5,726 human rabies deaths in India each year. The syllabus link is GS2 on health and GS3 on the regulation of pharmaceuticals.

Static syllabus linkage

1. Rabies is a dog-mediated zoonosis that is fatal once symptoms appear but fully preventable. Rabies is a viral disease caused by a Lyssavirus and transmitted to humans mainly through the bite or scratch of an infected animal; dogs account for the overwhelming majority of human cases in India. Once clinical symptoms appear, it is virtually always fatal, but timely post-exposure prophylaxis prevents it. Under WHO guidelines, exposures are graded into three categories, and the most severe (Category III) require wound washing, rabies vaccine and rabies immunoglobulin. Because the window for effective prevention is short, the quality of the vaccine at the moment of use decides life or death.
2. India aims to end dog-mediated rabies deaths by 2030 through a One Health plan. The WHO, the Food and Agriculture Organization, the World Organisation for Animal Health and the Global Alliance for Rabies Control launched the “Zero by 30” global strategic plan in 2018 to end human deaths from dog-mediated rabies by 2030. India launched its National Action Plan for Dog Mediated Rabies Elimination (NAPRE) by 2030 on World Rabies Day, September 28, 2021. The National Rabies Control Programme, run by the National Centre for Disease Control, covers the human side, including the supply of vaccine and immunoglobulin in public facilities. The animal side rests on mass dog vaccination and the Animal Birth Control Rules, 2023, framed under the Prevention of Cruelty to Animals Act, 1960.
3. The Drugs and Cosmetics Act defines spurious and misbranded drugs and punishes them severely. Section 17 of the Drugs and Cosmetics Act, 1940 defines a misbranded drug, Section 17A an adulterated drug and Section 17B a spurious drug — one that imitates or substitutes for another drug, or falsely bears the name of another manufacturer. Section 18 prohibits the manufacture and sale of such drugs. Under Section 27, as amended in 2008, manufacturing or selling a spurious or adulterated drug that is likely to cause death or grievous hurt is punishable with imprisonment of not less than ten years, which may extend to life, and a fine of not less than ₹10 lakh or three times the value of the drugs confiscated, whichever is more. “Counterfeit” is the everyday word; “spurious” is the legal one.
4. Vaccines pass through central lot release at the Central Research Institute, Kasauli. The Central Research Institute, Kasauli in Himachal Pradesh, established in 1905, functions under the Directorate General of Health Services and serves as the Central Drugs Laboratory for vaccines and sera. Every batch (lot) of a vaccine must be tested and released by it before it can be sold, which is the “independent government testing” IIL refers to. Manufacturing licences for vaccines are granted by State licensing authorities with the approval of the DCGI as the Central Licence Approving Authority, an example of the Centre-State “dual control” in drug regulation. Retail and wholesale sale licences, and raids such as Delhi’s, are the business of State drug controllers.

Why UPSC loves this

1. Neglected tropical diseases and zoonoses are recurring GS2 and GS3 themes. UPSC has asked about zoonotic diseases, the One Health approach and India’s elimination targets for diseases such as tuberculosis, kala-azar and lymphatic filariasis. Rabies, with a 2030 elimination goal and a large burden estimated by ICMR, fits this pattern, and a question on why India has struggled to eliminate it is plausible.
2. Spurious drugs and regulatory capacity recur in Mains. Drug quality has become a regular issue after contaminated cough syrup deaths and repeated seizures of fake medicines. This case adds a vaccine, which moves the question from consumer protection to public health, and a clean example of inter-State coordination between Delhi and Uttar Pradesh.
3. Prelims draws on institutions such as CRI Kasauli and on disease basics. Facts such as the causative agent of rabies, the vaccine production platform, the role of CRI Kasauli, and the year and target of NAPRE are exam-pattern material. Statement questions on which body grants vaccine licences also test the dual-control structure.

Analysis

1. A fake vaccine is worse than a fake pill because it fails silently. A spurious painkiller usually reveals itself when the pain does not go; a spurious rabies vaccine gives no signal at all until the disease appears, and by then nothing can be done. The victim may never be counted as a counterfeit case, because the death will be recorded as rabies. This makes counterfeit vaccines a hidden contributor to the 5,726 annual deaths estimated by ICMR. It also means post-market surveillance of vaccines cannot rely on complaints, as it does for many drugs, and must rely on supply-chain checks.
2. The August 27 alert shows the system worked late, not early. The DCGI wrote to all States about a misbranded batch almost four weeks before the Delhi seizure, and the manufacturer has confirmed the Delhi stock was never released. The alert thus did lead to action, which is to the credit of the regulators. But the stock had already reached a wholesale market in the capital, and the DDC is still tracing where else it went. The question an auditor would ask is how many doses were sold before the seizure, and whether patients who received them can be traced for re-vaccination. The paper does not answer this, and the public deserves to know.
3. Lot release protects the factory gate, not the supply chain. IIL correctly says every genuine batch is tested before release; but a counterfeit batch never passes through that gate at all. The weakness is downstream: purchases between wholesalers on invoices, which is how the Bhagirath Palace firm bought from Kanpur. Unique identifiers and track-and-trace systems, of the kind India has mandated through QR codes for active pharmaceutical ingredients and for top-selling brands under Schedule H2, are the logical extension. Extending verifiable codes to vaccines sold through private channels would let a pharmacist check authenticity in seconds.
4. Inter-State coordination is the real test of dual control. Delhi seized the stock, Uttar Pradesh raided the source, and the DCGI issued the national alert: three regulators acted, and the chain was found. This is dual control working as intended, but it depended on the firm naming its supplier and on informal cooperation. There is no single real-time national database of seizures and suspect batches that all State drug controllers use. A shared platform, maintained by CDSCO, would turn a one-off success into routine practice. Uniform capacity also matters: many States have far fewer drug inspectors than their pharmacies require.
5. Rabies elimination cannot be won on the vaccine side alone. The burden of 5,726 deaths is a result of dog bites, and NAPRE rests on mass dog vaccination and population management as much as on post-exposure prophylaxis. Every counterfeit dose weakens the human-side safety net precisely because the animal side is slow. Public facilities supplying free vaccine reduce the pull towards private purchase, where counterfeit stock is more likely to enter. Keeping stocks full in government health centres is therefore both a public health measure and an anti-counterfeiting measure.

Administrator's brainstorm